Globe Life Short Interest Climbs to Year High Before Results

Globe Life enters its Q3 earnings release with short sellers holding the largest position in at least a year, even as the rest of the positioning picture remains relaxed.

Short interest has risen 9% over the past month to 2.7% of the free float, roughly 2.15 million shares. That is a low absolute level, but it marks the highest reading in the ORTEX dataset. The climb has been gradual: shares short sat near 1.77 million in early September and have ground higher through October, touching 2.19 million on October 9 before easing slightly to 2.15 million.

The borrow market does nothing to amplify that bearish signal. Availability in the lending pool is effectively unlimited, with the cost to borrow running at 0.48%, down about 9% on the week and well below the late-September peak near 0.92%. There is no squeeze pressure, no tightening of borrow conditions, and no sign that the short position is under stress. Options positioning is equally muted: the put/call ratio of 0.18 is essentially flat against its 20-day average and sits toward the low end of the past year's range, with the 52-week high at 0.42.

Analyst coverage is broadly constructive heading into the print. JP Morgan raised its target to $195 last week, maintaining Overweight. Wells Fargo moved to $191 a few days earlier. Morgan Stanley was the outlier, trimming from $208 to $197 while keeping its Overweight rating. The consensus mean target of $193 sits about 14% above Wednesday's close of $169.62. Bulls point to the company's track record of low-double-digit EPS growth, driven by premium expansion, rising investment income, and active buybacks. Bears cite lower interest rate sensitivity, credit risks, and the lingering overhang from a prior short-seller report that depressed the stock's valuation multiples.

Insider activity has run consistently in one direction over recent months. The last disclosed open-market trades on record are all sales: the Co-Chairman and CEO sold roughly 50,000 shares in late July for around $9 million, the General Counsel sold a combined $4.2 million in August, and the Chief Investment Officer sold $1.7 million in late September. None of these trades were made under a pre-arranged 10b5-1 plan. Net insider selling over the 90 days to September 22 totalled around $31.8 million on a net basis. The only buying activity involved option exercises at legacy strike prices well below the current share price, standard compensation mechanics rather than discretionary conviction.

The Q3 print will test whether the company's EPS trajectory and agent count growth can hold the gap between the current share price and a consensus target that still sits meaningfully above it, even after months of steady insider selling.